Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020787 · ClinicalTrials.gov registry record · Phase 3
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
A Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00020787 is a Phase 3 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT00020787, a Phase 3 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- BIOLOGICAL G17DT Immunogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2001-07 |
| Est. Completion | 2002-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020787
The ClinicalTrials.gov registry entry for NCT00020787 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00020787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020787 about?
NCT00020787 is a clinical study titled "Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study th...
What is the current status of trial NCT00020787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2001-07. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00020787?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), G17DT Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00020787?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.